Literature DB >> 11379777

N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.

T Kita1, Y Tanigawara, S Chikazawa, H Hatanaka, T Sakaeda, F Komada, S Iwakawa, K Okumura.   

Abstract

Isoniazid (INH) is metabolized by polymorphic N-acetyltransferase2 (NAT2). In the present study, the relationship between the NAT2 genotype and the INH acetylator phenotype was examined in Japanese tuberculous patients and compared with healthy subjects. Subjects were classified according to the genotyping into NAT2*5B (allele4), NAT2*6A (allele3) and NAT2*7B (allele2), using the PCR-RFLP method. Twelve healthy subjects and 7 tuberculous patients participated in the INH acetylator phenotyping study, in which each subject was administered an oral dose of INH, followed by urine sampling for 24 h. Urinary concentrations of INH and N-acetylisoniazid (AcINH) were measured by the HPLC method. The urinary recoveries of INH (% of dose) in healthy subjects in relation to NAT2 genotyping were as follows: 6.4+/-2.2 in the homozygotes for the wild-type allele, 10.7+/-2.2 in the compound heterozygotes for the mutant allele, and 38.6+/-6.4 in the homozygotes for the mutant allele. In the patients study, the findings in the corresponding three groups were 4.0+/-1.7, 8.8 and 18.3+/-9.3. Although no significant difference was found because of the lower systemic exposure of INH in patients compared with healthy subjects, there were differences in the disposition kinetics of INH between subjects with and without mutations in the NAT2 gene, and these findings were observed not only in healthy subjects but also in patients who had comedicated drugs and hepatic dysfunctions. The findings indicated that the metabolism of INH by NAT2 is clearly impaired in subjects with mutations in the NAT2 gene, and thus genotyping for three NAT2 point mutations was adequate to predict the metabolism of INH in Japanese tuberculous patients as well as healthy subjects. This NAT2 genotyping could become a useful alternative to TDM for INH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11379777     DOI: 10.1248/bpb.24.544

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  11 in total

1.  Is there any difference between acetylator phenotypes in tuberculosis patients and healthy subjects?

Authors:  Hossein Khalili; Simin Dashti-Khavidaki; Mohsen Amini; Reza Mahjub; Mahboobeh Hajiabdolbaghi
Journal:  Eur J Clin Pharmacol       Date:  2010-03       Impact factor: 2.953

2.  Cornerstones of Toxicology.

Authors:  A Wallace Hayes; Darlene Dixon
Journal:  Toxicol Pathol       Date:  2017-01       Impact factor: 1.902

3.  Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.

Authors:  N Ben Fredj; R Gam; E Kerkni; A Chaabane; Z Chadly; N Boughattas; K Aouam
Journal:  Pharmacogenomics J       Date:  2016-04-19       Impact factor: 3.550

4.  Beta2-adrenergic receptor genotype-related changes in cAMP levels in peripheral blood mononuclear cells after multiple-dose oral procaterol.

Authors:  H Makimoto; T Sakaeda; K Nishiguchi; T Kita; T Sakai; F Komada; K Okumura
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

5.  Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b5 reductase activity.

Authors:  Mahmoud Abouraya; James C Sacco; Kristie Hayes; Sajeve Thomas; Craig S Kitchens; Lauren A Trepanier
Journal:  J Clin Pharmacol       Date:  2012-02       Impact factor: 3.126

6.  Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

Authors:  Martina Kinzig-Schippers; Dorota Tomalik-Scharte; Alexander Jetter; Bernhard Scheidel; Verena Jakob; Michael Rodamer; Ingolf Cascorbi; Oxana Doroshyenko; Fritz Sörgel; Uwe Fuhr
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

7.  N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.

Authors:  Shunichi Kumagai; Fusao Komada; Tomoko Kita; Akio Morinobu; Shoichi Ozaki; Hiroshi Ishida; Hajime Sano; Tsukasa Matsubara; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

8.  Clinical and Molecular Risk Factors of Anti-tubercular Therapy Induced Hepatitis.

Authors:  Premashis Kar; Rahul Karna; Rajesh Ruttala; Shilpa Arora; Anita Chakravarty; Suresh Kumar
Journal:  J Clin Exp Hepatol       Date:  2018-06-21

9.  NAT2 gene polymorphism: covert drug interaction causing phenytoin toxicity.

Authors:  C Adithan; A Subathra
Journal:  Indian J Med Res       Date:  2016-05       Impact factor: 2.375

10.  Role of pharmacogenomics in the treatment of tuberculosis: a review.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Pharmgenomics Pers Med       Date:  2012-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.